Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Practice Point
Nature Reviews Clinical Oncology 3, 22–23 (1 January 2006) | doi:10.1038/ncponc0380
Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy?
Abstract
Kabbinavar FF et al. (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23: 3706–3712 Synopsis Background Overall survival (OS) rates in patients with metastatic colorectal cancer (CRC) remain low.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
